Literature DB >> 18342779

Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.

Linda M Griffith1, Steven Z Pavletic, Stephanie J Lee, Paul J Martin, Kirk R Schultz, Georgia B Vogelsang.   

Abstract

Mesh：

Year:  2008        PMID： 18342779      PMCID： PMC2293302          DOI： 10.1016/j.bbmt.2008.01.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  22 in total

1.  Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.

Authors:  Howard M Shulman; David Kleiner; Stephanie J Lee; Thomas Morton; Steven Z Pavletic; Evan Farmer; J Margaret Moresi; Joel Greenson; Anne Janin; Paul J Martin; George McDonald; Mary E D Flowers; Maria Turner; Jane Atkinson; Jay Lefkowitch; M Kay Washington; Victor G Prieto; Stella K Kim; Zsolt Argenyi; A Hafeez Diwan; Asif Rashid; Kim Hiatt; Dan Couriel; Kirk Schultz; Sharon Hymes; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2006-01       Impact factor: 5.742

2.  Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007.

Authors:  James L M Ferrara; Claudio Anasetti; Edward Stadtmauer; Joseph Antin; John Wingard; Stephanie Lee; John Levine; Kirk Schultz; Frederick Appelbaum; Robert Negrin; Sergio Giralt; Christopher Bredeson; Helen Heslop; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2007-11       Impact factor: 5.742

3.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Authors:  Frédéric Baron; Michael B Maris; Brenda M Sandmaier; Barry E Storer; Mohamed Sorror; Razvan Diaconescu; Ann E Woolfrey; Thomas R Chauncey; Mary E D Flowers; Marco Mielcarek; David G Maloney; Rainer Storb
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

Authors:  Steven Z Pavletic; Paul Martin; Stephanie J Lee; Sandra Mitchell; David Jacobsohn; Edward W Cowen; Maria L Turner; Gorgun Akpek; Andrew Gilman; George McDonald; Mark Schubert; Ann Berger; Peter Bross; Jason W Chien; Daniel Couriel; J P Dunn; Jane Fall-Dickson; Ann Farrell; Mary E D Flowers; Hildegard Greinix; Steven Hirschfeld; Lynn Gerber; Stella Kim; Robert Knobler; Peter A Lachenbruch; Frederick W Miller; Barbara Mittleman; Esperanza Papadopoulos; Susan K Parsons; Donna Przepiorka; Michael Robinson; Michael Ward; Bryce Reeve; Lisa G Rider; Howard Shulman; Kirk R Schultz; Daniel Weisdorf; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2006-03       Impact factor: 5.742

5.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

6.  Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

Authors:  Kirk R Schultz; David B Miklos; Daniel Fowler; Ken Cooke; Judith Shizuru; Emmanuel Zorn; Ernst Holler; James Ferrara; Howard Shulman; Stephanie J Lee; Paul Martin; Alexandra H Filipovich; Mary E D Flowers; Daniel Weisdorf; Daniel Couriel; Peter A Lachenbruch; Barbara Mittleman; Georgia B Vogelsang; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

Review 7.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

8.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

9.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

10.  High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Nazmim S Bhuiya; Corey S Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531
View more
  9 in total

1.  The role of photopheresis in the treatment of graft-versus-host disease.

Authors:  J Klassen
Journal:  Curr Oncol       Date:  2010-04       Impact factor: 3.677

2.  The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.

Authors:  Suzanne van Dorp; Henrike Resemann; Liane te Boome; Floor Pietersma; Debbie van Baarle; Frits Gmelig-Meyling; Roel de Weger; Eefke Petersen; Monique Minnema; Henk Lokhorst; Saskia Ebeling; Scott J P Beijn; Edward F Knol; Marijke van Dijk; Ellen Meijer; Jürgen Kuball
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

Review 3.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

Review 4.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

Review 5.  State-of-the-art acute and chronic GVHD treatment.

Authors:  Muhammad Omer Jamil; Shin Mineishi
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

Review 6.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

7.  Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients.

Authors:  B C Norman; D A Jacobsohn; K M Williams; B K C Au; M A Au; S J Lee; C K Moravec; J W Chien
Journal:  Bone Marrow Transplant       Date:  2010-12-06       Impact factor: 5.483

Review 8.  Pathophysiology of GvHD and Other HSCT-Related Major Complications.

Authors:  Sakhila Ghimire; Daniela Weber; Emily Mavin; Xiao Nong Wang; Anne Mary Dickinson; Ernst Holler
Journal:  Front Immunol       Date:  2017-03-20       Impact factor: 7.561

9.  Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation.

Authors:  Catherine Lee; Sebastien Haneuse; Hai-Lin Wang; Sherri Rose; Stephen R Spellman; Michael Verneris; Katharine C Hsu; Katharina Fleischhauer; Stephanie J Lee; Reza Abdi
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.